Merck's Keytruda shown to extend lung cancer survival in two trials
CHICAGO (Reuters) - New trial results show that Merck& Co's Keytruda improves survival as a stand-alone treatment for newly diagnosed lung cancer and in combination with chemotherapy for hard-to-treat squamous cell lung cancer.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Health | Lung Cancer | Merck | Squamous Cell Carcinoma